Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 852
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by El-Saghir, N. S. Articles by Shamseddine, A. Search for Related Content PubMed Articles by El-Saghir, N. S. Articles by Shamseddine, A.

Abstract

Clinical characteristics and long-term survival of advanced breast cancer at the American University of Beirut Medical Center, Beirut, Lebanon

American University of Beirut, Beirut, Lebanon

852

Background: Based on our earlier reports of increased incidence of breast cancer in younger aged-groups at presentation, we decided to review the clinical characteristics, treatment patterns and survival data of our patients (pts) with breast cancer. Patients and Methods: Retrospective review of the medical records of all pts with breast cancer treated at our institution from 1990 to 2001. Patient demographics, clinical characteristics, pathology, staging, and treatment of 1328 patients were reviewed. Follow-up data available on 810 patients was analyzed for survival. Results: Overall: Total number was 1328 pts. 43.9% were premenopausal, and 56.1% postmenopausal. Mean age at diagnosis was 50.81± 12 years. We had 322 patients with advanced stages as follows: 249 pts had locally advanced (stage III) and 73 pts had metastatic disease (stage IV) at presentation. Stage III: patients: Total number 249 pts (18% of total). 46.1% were premenopausal and (53.9%) postmenopausal. Mean age at diagnosis was 49.5±12. 10 pts (4.2%) had breast-conserving surgery and 217 pts (91.9%) had mastectomy. 53.7% had positive hormonal receptors (ER+/PR+: 35.2%, ER+/PR–13%, ER–/PR+ 5.6%) and 46.3% had negative receptors. 172 pts (73.8%) had neo-adjuvant and adjuvant chemotherapy. 86.6% are alive after 2 years of diagnosis, 66.7% after 5 years, and 47.8% after 10 years. Stage IV: Total number 73 pts (5.4% of total). 40.6% were premenopausal and 59.4% postmenopausal. Mean age at diagnosis was 52.8±13. 6 pts (8.2%) had mastectomy 54.2% had positive hormonal receptors (ER+/PR+: 37.5%, ER+/PR–: 16.7%, ER–/PR+: 0%) and 45.8% had negative receptors. 55 pts (79.7%) had chemotherapy. 51% of pts are alive at 2 years of diagnosis and 21% at 5 years. Conclusions: Only 26% of our patients with breast cancer have locally advanced disease and metastatic disease. We confirm the younger mean age at presentation. Multi-modality treatment gave very good survival in locally advanced stage III disease with 47.8% of pts alive at 10 years. Most stage IV patients had chemotherapy in addition to hormonal therapy 51% of stage IV pts survived 2 years and 21% 5 years.

No significant financial relationships to disclose.